Johnson & Johnson to buy Israeli-based V-Wave for up to $1.7bn
The medtech firm develops implantable shunts designed to manage chronic heart failure
Johnson & Johnson announced on Tuesday it would buy Israel-based medical technology firm V-Wave for up to $1.7 billion.
The healthcare giant says the planned acquisition extends its position as a leader in addressing cardiovascular disease. V-Wave develops cardiovascular implant technology designed to manage chronic heart failure.
Its Ventura® Interatrial Shunt (IAS) is implanted in the heart through a minimally invasive procedure to help reduce heart failure and other cardiovascular events
Under the terms of the agreement, Johnson & Johnson said it will acquire V-Wave for an upfront payment of $600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately $1.1 billion. V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech.
Headquartered in Caesarea, Israel with other locations in the US, V-Wave was founded in 2009 by Yaacov Nitzan, Dr Ascher Shmulewitz and Dr Gad Keren. In 2013 the company completed animal trials of its shunt and in 2014 the first human implants were undertaken. Chief executive officer Dr Neal Eigler joined in early 2015 and has since overseen the development of the company’s senior management team, the evolution of its shunt products. The company is also led by president and head of European operations Erez Rozenfeld and chairman Dr Frank Litvack.
In 2016, V-Wave raised $70 million in a financing round led by Johnson & Johnson and Edwards and a few years later, secured a further $28 million led by Deerfield Management with the participation of Endeavour Vision, BRM, Aperture Venture Partners, Johnson & Johnson’s JJDC Fund, Pontifax, Quark Venture, Pura Vida, Triventures Fund, and Israel Secondary Fund.
Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech, said: “We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease. We recognize the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs.
“We know V-Wave well, with our relationship dating back to our original investment in the company in 2016, and we have a deep understanding of the technology and science, as well as the company’s commitment to patients. We look forward to working with the V-Wave team at this pivotal stage of its evolution to bring the Ventura® Interatrial Shunt technology to patients.”
Dr Neal Eigler, Chief Executive Officer of V-Wave, said: “At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission,” said Dr. Neal Eigler, Chief Executive Officer of V-Wave. “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible. I couldn’t be prouder of the V-Wave team, and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured.”
Thank you for helping to make Jewish News the leading source of news and opinion for the UK Jewish community. Today we're asking for your invaluable help to continue putting our community first in everything we do.
For as little as £5 a month you can help sustain the vital work we do in celebrating and standing up for Jewish life in Britain.
Jewish News holds our community together and keeps us connected. Like a synagogue, it’s where people turn to feel part of something bigger. It also proudly shows the rest of Britain the vibrancy and rich culture of modern Jewish life.
You can make a quick and easy one-off or monthly contribution of £5, £10, £20 or any other sum you’re comfortable with.
100% of your donation will help us continue celebrating our community, in all its dynamic diversity...
Engaging
Being a community platform means so much more than producing a newspaper and website. One of our proudest roles is media partnering with our invaluable charities to amplify the outstanding work they do to help us all.
Celebrating
There’s no shortage of oys in the world but Jewish News takes every opportunity to celebrate the joys too, through projects like Night of Heroes, 40 Under 40 and other compelling countdowns that make the community kvell with pride.
Pioneering
In the first collaboration between media outlets from different faiths, Jewish News worked with British Muslim TV and Church Times to produce a list of young activists leading the way on interfaith understanding.
Campaigning
Royal Mail issued a stamp honouring Holocaust hero Sir Nicholas Winton after a Jewish News campaign attracted more than 100,000 backers. Jewish Newsalso produces special editions of the paper highlighting pressing issues including mental health and Holocaust remembrance.
Easy access
In an age when news is readily accessible, Jewish News provides high-quality content free online and offline, removing any financial barriers to connecting people.
Voice of our community to wider society
The Jewish News team regularly appears on TV, radio and on the pages of the national press to comment on stories about the Jewish community. Easy access to the paper on the streets of London also means Jewish News provides an invaluable window into the community for the country at large.
We hope you agree all this is worth preserving.
